Company overview
ProteoNic Biosciences provides premium vector and transposon technology, including the 2G UNic® platform, to boost protein production in mammalian, yeast, and fungal cells for biopharmaceutical manufacturing. Their solutions enhance expression of complex proteins like multi-specific antibodies, fusion proteins, and viral vectors, improving productivity and titers. The company supports biologics R&D and production, with recent licensing of 2G UNic® to Ginkgo Bioworks for BARDA-funded anti-filovirus therapies.
Proteonic is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents, CDMO & Manufacturing partner serving United States & Americas. Core focus areas include proteonic biosciences, 2g unic technology, protein expression vectors, biologics manufacturing, viral vector production.
Industry categories: Life Science Reagents, CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://proteonic.nl
- Categories
- Life Science Reagents, CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- proteonic biosciences, 2g unic technology, protein expression vectors, biologics manufacturing, viral vector production
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What vector technologies does ProteoNic offer for protein production?
- ProteoNic offers premium vector technology and the proprietary 2G UNic® transposon platform, which boost transcription, translation, and productivity for complex proteins in mammalian, yeast, and fungal cells.
- What applications are supported by ProteoNic's solutions?
- Their technology supports production of therapeutic proteins, multi-specific antibodies, fusion proteins, and viral vectors, including lentiviral vectors with enhanced gRNA and infectious particle titers.
- Where is ProteoNic based and how can I contact them?
- ProteoNic is based in Leiden, The Netherlands. Contact VP Business Development Jonathan Frampton at [email protected] or visit their FAQ page for more details.
Related editorial coverage
- IPEC Excipient World Biologics Summit 2026: Recap
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
Explore lab tools and QA/QC resources for R&D teams.
